These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2478540)

  • 21. Regulation of the synthesis of C1 subcomponents and C1-inhibitor.
    Gulati P; Lemercier C; Guc D; Lappin D; Whaley K
    Behring Inst Mitt; 1993 Dec; (93):196-203. PubMed ID: 8172568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor.
    Ravindran S; Grys TE; Welch RA; Schapira M; Patston PA
    Thromb Haemost; 2004 Dec; 92(6):1277-83. PubMed ID: 15583734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue kallikrein is synthesized and secreted by human vascular endothelial cells.
    Yayama K; Kunimatsu N; Teranishi Y; Takano M; Okamoto H
    Biochim Biophys Acta; 2003 Feb; 1593(2-3):231-8. PubMed ID: 12581867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
    Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS
    Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol.
    Pappalardo E; Zingale LC; Cicardi M
    Immunol Lett; 2003 May; 86(3):271-6. PubMed ID: 12706530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema.
    Kramer J; Katz Y; Rosen FS; Davis AE; Strunk RC
    J Clin Invest; 1991 May; 87(5):1614-20. PubMed ID: 1902490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay.
    Kaplan AP; Gruber B; Harpel PC
    Blood; 1985 Sep; 66(3):636-41. PubMed ID: 3875374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema.
    Kramer J; Rosen FS; Colten HR; Rajczy K; Strunk RC
    J Clin Invest; 1993 Mar; 91(3):1258-62. PubMed ID: 8450054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema.
    Cicardi M; Igarashi T; Rosen FS; Davis AE
    J Clin Invest; 1987 Mar; 79(3):698-702. PubMed ID: 3818946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon.
    Ariga T; Igarashi T; Ramesh N; Parad R; Cicardi M; Davis AE
    J Clin Invest; 1989 Jun; 83(6):1888-93. PubMed ID: 2723063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays.
    Nuijens JH; Huijbregts CC; Cohen M; Navis GO; de Vries A; Eerenberg AJ; Bakker JC; Hack CE
    Thromb Haemost; 1987 Aug; 58(2):778-85. PubMed ID: 2445044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
    Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP
    J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New and rapid functional assay for C1 inhibitor in human plasma.
    Schapira M; Silver LD; Scott CF; Colman RW
    Blood; 1982 Apr; 59(4):719-24. PubMed ID: 6174161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C1-inhibitor--biochemical properties and clinical applications.
    Al-Abdullah IH; Greally J
    Crit Rev Immunol; 1985; 5(4):317-30. PubMed ID: 3899511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficient expression of human C1-inhibitor in CHO cells by using a dicistronic expression vector].
    Yang H; Zheng S
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Feb; 19(1):41-7. PubMed ID: 10453551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C1 inhibitor and diagnosis of hereditary angioedema in newborns.
    Nielsen EW; Johansen HT; Holt J; Mollnes TE
    Pediatr Res; 1994 Feb; 35(2):184-7. PubMed ID: 8165053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure and function of C1 inhibitor.
    Davis AE
    Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor.
    Gluszko P; Undas A; Amenta S; Szczeklik A; Schmaier AH
    J Lab Clin Med; 1994 Feb; 123(2):232-40. PubMed ID: 8301199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.
    Prandini MH; Reboul A; Colomb MG
    Biochem J; 1986 Jul; 237(1):93-8. PubMed ID: 3099750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A rapid method for functional determination of C1 esterase inhibitor in plasma.
    Cullmann W; Kövary PM; Dick W; Czarnetzki B; Echternach-Happle K
    Clin Chim Acta; 1982 Mar; 119(3):237-42. PubMed ID: 6175450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.